Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-02-14 4:27 pm Purchase |
2022-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Redmile Group LLC | 2,673,837 4.900% |
86,107 (+3.33%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Baker Bros. Advisors LP | 2,879,825 5.200% |
2,879,825 (New Position) |
Filing History |
| 2023-02-14 12:38 pm Sale |
2022-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
PRICE T ROWE ASSOCIATES INC | 4,379,159 8.000% |
-845,527 (-16.18%) |
Filing History |
| 2023-02-14 09:37 am Purchase |
2022-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
AVORO CAPITAL ADVISORS LLC | 3,850,000 7.000% |
3,850,000 (New Position) |
Filing History |
| 2023-02-09 11:25 am Purchase |
2022-12-30 | 13G | Kymera Therapeutics, Inc. KYMR |
The Vanguard Group | 3,660,307 6.670% |
703,133 (+23.78%) |
Filing History |
| 2023-02-08 2:16 pm Purchase |
2022-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
STATE STREET CORP STT |
2,846,221 5.190% |
2,846,221 (New Position) |
Filing History |
| 2023-02-06 3:02 pm Purchase |
2022-12-30 | 13G | Kymera Therapeutics, Inc. KYMR |
WELLINGTON MANAGEMENT CO LLP | 4,591,089 8.370% |
1,896,275 (+70.37%) |
Filing History |
| 2023-02-01 4:54 pm Sale |
2022-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
BLACKROCK INC BLK |
3,334,901 6.100% |
-62,639 (-1.84%) |
Filing History |
| 2022-08-23 4:45 pm Purchase |
2022-08-22 | 13D | Kymera Therapeutics, Inc. KYMR |
BIOTECHNOLOGY VALUE FUND L P | 4,692,604 8.600% |
553,846 (+13.38%) |
Filing History |
| 2022-07-11 2:10 pm Purchase |
2022-06-30 | 13G | Kymera Therapeutics, Inc. KYMR |
PRICE T ROWE ASSOCIATES INC | 5,224,686 10.100% |
1,674,158 (+47.15%) |
Filing History |
| 2022-06-01 5:00 pm Purchase |
2022-05-27 | 13D | Kymera Therapeutics, Inc. KYMR |
BIOTECHNOLOGY VALUE FUND L P | 4,138,758 8.000% |
552,100 (+15.39%) |
Filing History |
| 2022-02-14 5:07 pm Sale |
2021-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Redmile Group LLC | 2,587,730 5.000% |
-132,759 (-4.88%) |
Filing History |
| 2022-02-14 2:34 pm Purchase |
2021-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
PRICE T ROWE ASSOCIATES INC | 3,550,528 6.900% |
3,550,528 (New Position) |
Filing History |
| 2022-02-11 5:09 pm Sale |
2021-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Atlas Venture Fund X L.P. | 5,763,012 11.200% |
-2,185,970 (-27.50%) |
Filing History |
| 2022-02-10 08:22 am Purchase |
2021-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
The Vanguard Group | 2,957,174 5.750% |
2,957,174 (New Position) |
Filing History |
| 2022-02-09 09:22 am Sale |
2022-02-08 | 13G | Kymera Therapeutics, Inc. KYMR |
FMR CORP | 2,347,527 4.568% |
-94,533 (-3.87%) |
Filing History |
| 2022-02-04 4:12 pm Purchase |
2021-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
BLACKROCK INC BLK |
3,397,540 6.600% |
3,397,540 (New Position) |
Filing History |
| 2022-02-04 09:27 am Purchase |
2021-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
WELLINGTON MANAGEMENT CO LLP | 2,694,814 5.240% |
2,694,814 (New Position) |
Filing History |
| 2022-01-31 5:07 pm Purchase |
2022-01-27 | 13D | Kymera Therapeutics, Inc. KYMR |
BIOTECHNOLOGY VALUE FUND L P | 3,586,658 7.000% |
955,996 (+36.34%) |
Filing History |
| 2021-02-16 5:27 pm Purchase |
2020-12-31 | 13G | Kymera Therapeutics, Inc. KYMR |
Atlas Venture Fund X L.P. | 7,948,982 17.900% |
7,948,982 (New Position) |
Filing History |